FDA.reportPublic FDA data

ranibizumab-eqrn 0.3 MG in 0.05 ML Injection

RxCUI
2612675
RxNorm name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Display name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Full name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:24

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761165Cimerliranibizumab-eqrn351(k) InterchangeableRx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CIMERLIRANIBIZUMAB-EQRNCoherus BioSciences Ince0e23118-1490-a554-e053-2995a90ab90c2025-05-07Warnings, Adverse reactionsExact identifier
rxcui: 2612675
CIMERLIRANIBIZUMAB-EQRNSandoz Inc4b383d74-4830-4587-95f7-c32a39268df72024-06-17Warnings, Adverse reactionsExact identifier
rxcui: 2612675

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
e0e23118-1490-a554-e053-2995a90ab90cranibizumab-eqrn 0.3 MG in 0.05 ML Injection [PSN] · 0.05 ML ranibizumab-eqrn 6 MG/ML Injection [SCD] · ranibizumab-eqrn 0.3 MG per 0.05 ML Injection [SY] · ranibizumab-eqrn 6 MG/ML per 0.05 ML Injection [SY]412These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet20250507
4b383d74-4830-4587-95f7-c32a39268df7ranibizumab-eqrn 0.3 MG in 0.05 ML Injection [PSN] · 0.05 ML ranibizumab-eqrn 6 MG/ML Injection [SCD] · ranibizumab-eqrn 0.3 MG per 0.05 ML Injection [SY] · ranibizumab-eqrn 6 MG/ML per 0.05 ML Injection [SY]43These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20240617